期刊文献+

基于文献分析的帕米膦酸二钠不良反应初步评估 被引量:2

Primary evaluation on adverse drug reactions of pamidronate based on literature analysis
原文传递
导出
摘要 目的:分析帕米膦酸二钠不良反应的发生规律及特点,为合理用药提供参考。方法:检索1995-2014年4月"中国学术期刊全文数据库(CNKI)"、"维普中文科技期刊数据库(VIP)"收载的帕米膦酸二钠不良反应文献进行分析。结果:22例不良反应中,男13例,女9例,年龄50岁以上患者较多(16例,72.8%),用药1周内出现不良反应9例(40.9%),用药1年后出现不良反应7例(31.8%),累及的器官或系统以肌肉骨骼系统损害为主(11例,50.0%)。结论:临床医师、药师应了解帕米膦酸二钠致不良反应的规律和特点,加强用药监测,减少不良反应的发生。 OBJECTIVE To analyze the general patterns and characteristics of adverse drug reactions(ADRs)induced by Pamidronate(APD)and provide references for clinical medication.METHODS ADRs of APD reported from1995 to April2014 retrieved in CNKI and VIP were collected and analyzed statistically.RESULTS Totally 22 cases of ADRs caused by APD were collected,including 13 men and 9 women.Patients over the age of 50 years showed the highest incidence(n=16,72.8%).Nine cases of ADRs caused by APD attacked within 1 week after injection and 7 cases of ADRs 1 year layer.The ADRs were mainly involved in disorders of musculoskeletal system(n=11,50.0%).CONCLUSION Clinicians and pharmacists should be familiar the patterns and characteristics of ADRs induced by APD,and closely monitoring pamidronate administration to reduce relevant ADRs.
作者 程军
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2015年第6期528-531,共4页 Chinese Journal of Hospital Pharmacy
关键词 帕米膦酸二钠 药物不良反应 文献分析 pamidronate adverse drug reactions literature analysis
  • 相关文献

参考文献7

二级参考文献35

  • 1陈曦,田炳如.帕米磷酸二钠治疗恶性肿瘤骨转移及多发性骨髓瘤骨痛[J].临床医学,2007,27(3):55-56. 被引量:10
  • 2Marx RE.Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws:a growing epidemic[J].J Oral Maxillofac Surg,2003,61:1115-1117.
  • 3Cesar AM.Bisphosphonate-associated osteonecrosis of mandibularand maxillary bone:an emerging oral complication of supportive cancer therapy[J].Cancer,2005,104 (1):83-93.
  • 4Marx R E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws:a growing epidemic [J]. J Oral Maxillofac Surg, 2003,61 (9) .. 1115-1117.
  • 5Odvina C V, Zerwekh J E, Rao D S, et al. Severely sup- pressed bone turnover: a potential complication of alen- dronate therapy[J]. J Clin Endocrinol Metab, 2005, 90(3): 1294-1301.
  • 6Grey A, Reid I R. Differences between the bisphosphonates for the prevention and treatment of osteoporosis[J]. Tiler Clin Risk Manag, 2006, 2(1) : 77-86.
  • 7Hewitt C, Farah C S. Bisphosphonate-related osteonecrosis of the jaws: a comprehensive review[J]. J Oral Pathol Med, 2007, 36(6):319-328.
  • 8Cheng A, Mavrokokki A, Carter G, et al. The dental im- plications of bisphosphonates and bone disease[J]. Aust DentJ, 2005, 50(4Supp12):S4-S13.
  • 9Kikuiri T, Kim I, Yamaza T, et al. Cell-based im- munotherapy with mesenchymal stem ceils cures bisphos- phonate-related osteonecrosis of the jaw-like disease in mice [J]. J Bone Miner Res, 2010, 25(7): 1668-1679.
  • 10Hokugo A, Christensen R, Chung E M, et al. Increased prevalence of bisphosphonate-related osteonecrosis of the jaw with vitamin D deficiency in rats [J]. J Bone Miner Res, 2010, 25(6): 1337-1349.

共引文献24

同被引文献9

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部